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Abstract
Background:  Proteolytic  Clostridium botulinum is the causative agent of botulism, a severe
neuroparalytic illness. Given the severity of botulism, surprisingly little is known of the population
structure, biology, phylogeny or evolution of C. botulinum. The recent determination of the genome
sequence of C. botulinum has allowed comparative genomic indexing using a DNA microarray.
Results: Whole genome microarray analysis revealed that 63% of the coding sequences (CDSs)
present in reference strain ATCC 3502 were common to all 61 widely-representative strains of
proteolytic C. botulinum and the closely related C. sporogenes tested. This indicates a relatively stable
genome. There was, however, evidence for recombination and genetic exchange, in particular
within the neurotoxin gene and cluster (including transfer of neurotoxin genes to C. sporogenes),
and the flagellar glycosylation island (FGI). These two loci appear to have evolved independently
from each other, and from the remainder of the genetic complement. A number of strains were
atypical; for example, while 10 out of 14 strains that formed type A1 toxin gave almost identical
profiles in whole genome, neurotoxin cluster and FGI analyses, the other four strains showed
divergent properties. Furthermore, a new neurotoxin sub-type (A5) has been discovered in strains
from heroin-associated wound botulism cases. For the first time, differences in glycosylation
profiles of the flagella could be linked to differences in the gene content of the FGI.
Conclusion: Proteolytic C. botulinum has a stable genome backbone containing specific regions of
genetic heterogeneity. These include the neurotoxin gene cluster and the FGI, each having evolved
independently of each other and the remainder of the genetic complement. Analysis of these
genetic components provides a high degree of discrimination of strains of proteolytic C. botulinum,
and is suitable for clinical and forensic investigations of botulism outbreaks.
Background
The species Clostridium botulinum consists of a group of
four physiologically and phylogenetically distinct Gram-
positive obligately anaerobic bacteria that share the com-
mon feature of producing the highly potent botulinum
neurotoxin [1]. Organisms belonging to two of these
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groups are associated with the majority of cases of human
botulism. C. botulinum Group I (proteolytic C. botulinum)
is a mesophilic organism that is responsible for food-
borne botulism, wound botulism, adult intestinal botu-
lism and infant botulism. C. sporogenes is considered to be
a non-toxigenic version of proteolytic C. botulinum [2]. C.
botulinum Group II (non-proteolytic C. botulinum) is a psy-
chrotrophic organism associated with most cases of food-
borne botulism not attributed to Group I [3,4]. The
botulinum neurotoxins are the most potent toxins
known, with as little as 30–100 ng constituting a poten-
tially fatal dose [5], and are considered to be a bioterror-
ism threat [6].
Seven major types of botulinum neurotoxin (types A to
G), and a significant number of sub-types have been
described. For example, four sub-types of type A toxin
(termed A1, A2, A3, A4) have been identified [7-9]. Sub-
types are defined as differing by at least 2.6% at the amino
acid level [7,10]. Proteolytic C. botulinum strains form
neurotoxin of types A, B, or F, and dual-toxin forming
strains have also been described [2]. Additionally, some
strains possess two neurotoxin genes, but only form one
active neurotoxin. For example, A(B) strains possess a type
A and type B neurotoxin gene, but only form type A neu-
rotoxin. Non-proteolytic C. botulinum strains form a single
neurotoxin of types B, E, or F. Each neurotoxin protein
comprises a light chain and heavy chain. The light chains
possess endopeptidase activity and cleave proteins in the
SNARE complex leading to flaccid muscle paralysis, and
potentially respiratory failure [11].
The neurotoxin genes are associated with other genes
within the neurotoxin cluster, and two major cluster types
are recognised. The most studied neurotoxin cluster in
proteolytic C. botulinum is termed the ha plus/orf-X minus
cluster. It is commonly associated with type A1 and type B
neurotoxin genes [9,12,13], and is present in the genome
of the sequenced type A1 strain ATCC 3502 used as a
hybridisation reference in this work [14]. This cluster
comprises genes for the neurotoxin (cntA), three haemag-
glutinins (HA) (cntC, cntD, cntE), non-toxic-non-haemag-
glutinin (NTNH) (cntB), and a positive regulatory protein
(cntR). The second cluster type is called the ha minus/orf-
X plus cluster. In the case of proteolytic C. botulinum, this
cluster is most frequently associated with type A2, A3, A4
and F toxin genes, and the type A1 gene in A(B) strains
[9,12,13]. This cluster includes genes for the neurotoxin,
NTNH and CntR (historically also known as p21 [9,13]),
lacks the three genes encoding HA, and additionally con-
tains a group of three open reading frames (orf-X1, orf-X2,
orf-X3) and a single CDS (coding sequence) (p47) all of
unknown function.
The genome sequence of proteolytic C. botulinum strain
ATCC 3502 (NCTC 13319, Hall 174) has been recently
completed, and consists of a chromosome (3.9 Mbp) and
plasmid (16.3 kbp), which contain 3,650 and 19 coding
sequences (CDSs), respectively [14]. A DNA microarray
was designed based on this sequence, and initial tests
revealed that two prophages and a plasmid present in the
genome of strain ATCC 3502 were absent from 11 test
strains of proteolytic C. botulinum and C. sporogenes, and
that the DNA microarray could be used to discriminate
between strains of proteolytic C. botulinum [14]. The 11
test strains shared a minimum of 84% of the CDSs of
ATCC 3502, but were significantly diverged from other
sequenced clostridial species, demonstrating the wide
phylogenetic distance between different clostridia [14].
The flagellar glycosylation island (FGI) also showed evi-
dence of diversity between strains of proteolytic C. botuli-
num  [14]. The ATCC 3502 genome contains a large
putative FGI comprising CDSs CBO2666-2729. These are
flanked by the CDSs for flagellar structural proteins FlgB
(CBO2665), FliD and the flagellin structural subunits
FlaA1 (CBO2730) and FlaA2 (CBO2731). The FGI can be
divided into two distinct regions [14]. CBO2678-2689 are
CDSs similar to those involved in capsular polysaccharide
biosynthesis in Group B Streptococcus (designated FGI-I,
flanked by putative flagellin structural genes CBO 2666
and CBO 2695), whereas CBO2696-2729 represent CDSs
with sequence similarity to those involved in the modifi-
cation of Campylobacter jejuni flagellins with nonulosonic
acids (designated FGI-II, CBO2696-CBO2729) [14].
In order to extend our understanding of phylogenetic rela-
tionships and the biology of proteolytic C. botulinum, an
extensive comparative genomic indexing study has been
carried out involving 58 strains of proteolytic C. botuli-
num, 2 strains of non-proteolytic C. botulinum, and 3
strains of C. sporogenes using DNA microarrays based on
the genome sequence of strain ATCC 3502. We have
assessed the evolution of the neurotoxin gene and cluster
and flagellar glycosylation island (FGI) in relation to the
remainder of the genetic complement. We have also iden-
tified important links between CDSs contained within the
FGI and sugars associated with post-translational modifi-
cation of flagella, and discovered a new neurotoxin A sub-
type associated with UK wound botulism cases.
Methods
Bacterial strains and preparation of DNA
C. botulinum and C. sporogenes strains used in this work,
together with the type of neurotoxin formed, their origin,
source and date of isolation are listed in Table 1. Before
use, all strains were checked for purity (consistent colony
morphology) and lack of contamination by growth on
PYGS plates under both aerobic and anaerobic atmos-
pheres [15]. Proteolytic activity was determined by growth
on Reinforced Clostridial Medium (RCM) containing 5%
(w/v) skim milk [16] and lipase activity on McClungBMC Genomics 2009, 10:115 http://www.biomedcentral.com/1471-2164/10/115
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Table 1: Summary of details of Clostridium strains tested in microarray.
Bacterium and toxin type Strain Origin Location (year) source
Proteolytic C. botulinum
A1 ATCC 3502 Foodborne botulism? (canned peas) California, USA (early 1920s) IFR
A1 NCTC 3805 Environment (bovine) Nevada, USA (1919) IFR
A1 VL1 Environment (ham) Netherlands (1970s) IFR
A1 16037 Foodborne botulism (canned tomato juice) Idaho, USA (1974) IFR
A1 ATCC 25763 Foodborne botulism/environment? unknown IFR
A1 96A Foodborne botulism/environment? unknown IFR
A1 CDC 1690 Foodborne botulism (home canned spaghetti) Tennessee, USA (1977) IFR
A1 NCTC 7272 Environment? (before 1947) IFR
A1 17A Foodborne botulism/environment? unknown (1963) HC
A1 F9801A Infant botulism (faeces) Quebec, Canada (1998) HC
A1 FE0101AJO Foodborne botulism (faeces) Quebec, Canada (2001) HC
A1 FE0205A1AK Infant botulism (faeces) Alberta, Canada (2002) HC
A1 F9604A Infant botulism (faeces) Alberta, Canada (1996) HC
A1 MUL0109ASA Environment (mullet fish) Gulf of Kuwait, Kuwait (2001) HC
A2 NCTC 9837 Foodborne botulism (canned fish) London, UK (1955) IFR
A2 ZK3 Environment (ground nuts) Bedford, UK (1950s) IFR
A3 NCTC 2012 Foodborne botulism (wild duck paste) Loch Maree, UK (1922) IFR
A1(B) NCTC 11199 Infant botulism (faeces) Southend, UK (1978) IFR
A1(B) CDC 5001 Foodborne botulism (sautéed onions) Illinois, USA (1983) IFR
A1(B) CDC 13280 Foodborne botulism (home canned peppers) Colorado, USA (1972) IFR
A1(B) MDa10 Infant botulism (faeces) USA (1980s) IFR
A1(B) NCTC 2916 Foodborne botulism (canned corn) Colorado, USA (1929) IFR
A1(B) FE0207AMB Foodborne botulism (faeces) Ontario, Canada (2002) HC
A1(B) FE0303A1YO Infant botulism (faeces) Ontario, Canada (2003) HC
A1(B) FE9504ACG Infant botulism (faeces) Quebec, Canada (1995) HC
A1(B) FE9909ACS Infant botulism (faeces) Alberta, Canada (1999) HC
A1(B) PE0101AJO Foodborne botulism (pork cutlets) Quebec, Canada (2001) HC
A1(B) FE0602ALS Infant botulism (faeces) Alberta, Canada (2006) HC
A1(B) CJ0611A Foodborne botulism (carrot juice) Ontario, Canada (2006) HC
A1b CDC 588 Foodborne botulism (home canned carrots) Ohio, USA (1976) IFR
Ba4 CDC 657 Infant botulism (faeces) Texas, USA (1976) IFR
A5(B) H0 4244 0055 Wound botulism (pus) Sheffield, UK (2004) IFR
A5(B) H0 4402 065 Wound botulism (pus) Dudley, UK (2004) IFR
A5(B) H0 4464 107 Wound botulism (wound) Manchester, UK (2004) IFR
A5(B) H0 4068 0341 Wound botulism (wound) London, UK (2004) IFR
B NCTC 7273 Foodborne botulism? (beans?) UK? (before 1947) IFR
B 2345 Foodborne botulism/environment? (before 1970s) IFR
B NCTC 3815 Environment? (cheese)? USA (1930s) IFR
B BL81/25 Foodborne botulism/environment? unknown IFR
B 213B Foodborne botulism/environment? unknown IFR
B BL 143 Environment (fish) Bedford, UK (1969) IFR
B BL 150 Environment (fish) Bedford, UK (1970) IFR
B CDC 15044 Foodborne botulism (home canned blackberries) Kentucky, USA (1973) IFR
B NCIB 4301 Foodborne botulism/environment? unknown IFR
B CDC 7827 Infant botulism (faeces) Nevada, USA (1991) IFR
B IB1-B Infant botulism (faeces) Ontario, Canada (1979) HC
B 368B Infant botulism (faeces) California, USA (1976) HC
B 920A276 Infant botulism (faeces) California, USA (1976) HC
B FE0507BLP Infant botulism (faeces) Ontario, Canada (2005) HC
B 13441-77 Infant botulism (faeces) California, USA (1977) HC
B MRB Foodborne botulism (mushrooms) Quebec, Canada (1973) HC
Bf CDC 3281 Infant botulism (faeces) New Mexico, USA (1980) IFR
Bf FE9508BRB Foodborne botulism (faeces) Quebec, Canada (1995) HC
Bf FE9508BPD Foodborne botulism (faeces) Quebec, Canada (1995) HC
Bf PA9508B Foodborne botulism (pâté) Quebec, Canada (1995) HCBMC Genomics 2009, 10:115 http://www.biomedcentral.com/1471-2164/10/115
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Toabe egg yolk medium [17]. Strains were also checked
for presence of type A, B and F neurotoxin genes by PCR
using 100 ng genomic DNA as template with primer pairs
NKB-1 (5'-GATACATTTACAAATCCTGAAGGAGA-3') and
NKB-5 (5'-AACCGTTTAACACCATAAGGGATCATAGAA-
3') which generate a 2278 bp PCR product for the type A
neurotoxin gene; B-1A (5'-GATGGAACCATTTGCTAG-3')
and B2-D (5'-AACATCAATACATATTCCTGG-3') which
generate a 1284 bp PCR product for the type B neurotoxin
gene [18]; and BONTFF2 (5'-GTGCTTATTATGATC-
CTAATTATTTAACC-3') and BONTFR2 (5'-CCATACTTC-
CATTGAAAATAATCTTTATA-3') which, using the same
reaction conditions, give a 765 bp PCR product for the
type F neurotoxin gene (data not shown). The type(s) of
neurotoxins formed by each strain was established by
sero-neutralisation and the mouse bioassay [19,20].
Genomic DNA was purified from exponentially growing
cells, digested with Sau3A1 and labelled with fluorescent
nucleotides as previously described [14] except that Cy5-
or Cy3-dUTP (GE Healthcare, UK) was substituted for
Cy5- or Cy3-dCTP. The isolation of plasmid DNA fol-
lowed the method outlined by O'Sullivan and Klaenham-
mer [21]. For restriction enzyme analysis, the
manufacturer protocols (New England BioLabs, USA)
were followed with the addition of spermidine to a final
concentration of 4 mM. Digests were analyzed by stand-
ard gel electrophoresis in 1.5% agarose.
Construction of the C. botulinum ATCC 3502 DNA 
microarray
The microarray [14] included probes for 3433 genomic
CDS, for 19 CDSs of plasmid pBOT3502, and for neuro-
toxin-associated genes absent in strain ATCC 3502. These
included probes for CDSs of the gene clusters commonly
associated with neurotoxins type A2, A3, A4 and F (i.e.
p47, orf-X1, orf-X2, orf-X3 and lycA); for cntR of type F; and
two probes each (N- and C-terminus probes) for cntA
(neurotoxin CDS) of types A, B, and F. Probes were
designed using GenBank database sequences (available in
July 2005), and PCR amplified using DNA from strains
NCTC 9837 (p47, orf-X1, orf-X2, orf-X3 and lycA), Lange-
land (cntR/F, cntA/F-N and cntA/F-C), ATCC 3502 (cntA/A-
N and cntA/A-C), and NCTC 3815 (cntA/B-N and cntA/B-
C). The microarray probe to the haemagglutinin gene cntC
(CBO0803; previously ha34) failed to give a satisfactory
signal and these microarray data were excluded from the
analysis. The overall extent of genome coverage is similar
to that achieved previously for other DNA microarrays
[22-24]. GenBank accession numbers for genomes used in
this work are: A1 strain ATCC 3502, AM412317; ATCC
3502 plasmid pBOT3502, AM412318; A1 strain ATCC
19397, CP000726; A3 strain Loch Maree, CP000962; F
strain Langeland, CP000728; A1(B) strain NCTC 2916,
NZ_ABDO00000000 (genome in progress); strain Bf,
NZ_ABDP00000000 (genome in progress); C. sporogenes
strain ATCC 15579, NZ_ABKW00000000 (genome in
progress). The microarray design has been deposited with
ArrayExpress (accession number A-MEXP-791).
Microarray hybridisation and data analysis
Each experiment combined 2 μg Cy5-dUTP-labelled
ATCC 3502 (reference) DNA and 2 μg Cy3-dUTP-labelled
test DNA, and was performed on a minimum of four
probe set replicates as described previously [14]. DNA
microarrays were scanned using an Axon GenePix 4000B
microarray laser scanner (Axon Instruments, CA, USA).
The data from detected features was initially processed
using the GenePix Pro v.6.0 software supplied with the
scanner.
The R package arrayMagic v.1.14.0 [25] was used to assess
the quality of the hybridisations by generating a diagnos-
tic plot showing the pairwise similarities between all
hybridisations. The pairwise similarity score (Sab) was cal-
culated by arrayMagic via Sab = MADi(Xia - Xib), where for
each pair of arrays (a and b) Xia is the log-ratio of the i-th
probe on the a-th array, and the MAD (median absolute
deviation) is taken over all CDSs. The hierarchical cluster-
ing diagram generated used the similarity scores as a
measure of the 'distance' between arrays. In this way the
fidelity of the microarray technical replicates could be
assessed (arrayMagic's R script, experiment description
file and diagnostic plot are available on request). The data
F Langeland Foodborne botulism (liver paste) Langeland, Denmark (1960) HC
F Walls 8G Environment (crab) Virginia, USA (1968) IFR
F H461297F Environment (honey) Wisconsin, USA (1998) HC
C. sporogenes
NCIMB 10696 Environment (soil) USA (1920s?) IFR
NCDO 1792 Environment (aseptic cheese) Reading, UK? (1960s?) IFR
NCDO 1710 Gas gangrene London, UK (1920) IFR
Non-proteolytic C. botulinum
E GA9709EHS Foodborne botulism (gastric liquid) Quebec, Canada (1997) HC
E HNB0804E Environment (honey) New Brunswick, Canada (2004) HC
Source: IFR = IFR culture collection; HC = Health Canada culture collection.
Table 1: Summary of details of Clostridium strains tested in microarray. (Continued)BMC Genomics 2009, 10:115 http://www.biomedcentral.com/1471-2164/10/115
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for replicates that did not group together were discarded
and the hybridisation experiments repeated with a fresh
preparation of genomic DNA. Array data were further ana-
lysed using the GeneSpring GX package (Agilent Technol-
ogies) using Lowess normalisation. In order to correct for
uneven printing or for probes which routinely gave a high
or low signal, data were further normalised by using as a
control hybridisation data from ATCC 3502 × ATCC 3502
dye-swap experiments (four microarrays) on a per CDS
basis.
Pearson Correlation coefficients were calculated for the
normalised signal ratios associated with probes for all
chromosomal and pBOT3502 CDSs and used to create a
similarity matrix for all 61 strains of proteolytic C. botuli-
num and C. sporogenes. The similarity matrix was subjected
to the average linkage clustering method using Gene-
Spring GX software.
The data generated by probes for neurotoxin cluster genes
not found in ATCC 3502 were processed separately as
there was no competing reference DNA during hybridisa-
tion. Whereas a signal channel ratio of 0.55 was taken as
the cut-off between a presence or absence of hybridisation
for chromosomal genes, a ratio greater than 5.0 was taken
as a positive hybridisation for CDSs not in ATCC 3502.
This gave results that agreed well with known genome
sequences of C. botulinum in the GenBank database. Data
for probes to the ATCC 3502 neurotoxin gene cluster itself
used a cut-off point of 0.40 to compensate for the fact that
all hybridisations had been performed using ATCC 3502
DNA as the reference material.
Validation of microarray
The microarray data were validated for biological signifi-
cance using CDSs within the clostridial flagellar glycosyla-
tion island (FGI) and plasmid pBOT3502. The DNA
sequence of 28 CDSs from the FGI-I (Figures 1 and 2) of
ATCC 3502 and proteolytic C. botulinum type F strain
Langeland, matched by annotation using genomic context
and BlastP, was compared to the signals observed by
microarray analysis. The highest sequence similarity
between two homologous CDSs (CBO2682 and
CLI_2747) corresponding to an absence of microarray
hybridisation was 84.8%. The lowest sequence similarity
between two homologous CDSs (CBO2683 and
CLI_2748) that hybridised to the microarray was 85.7%,
giving a minimum value of approximately 85% sequence
identity between CDSs for a positive microarray hybridi-
sation result. A similar percentage was previously reported
for studies with Candida [26] and Helicobacter pylori [27].
Further validation was carried out by analysis of data for
the 19 probes to the plasmid pBOT3502. Using a cut-off
value of 0.30 (because of very high signals), only one
strain, F9801A, gave a positive microarray signal for all 19
CDSs (Figure 3). Subsequent tests demonstrated that this
strain, but not two others that were tested, contained a
plasmid that shared identical restriction sites to that of
pBOT3502 (Figure 4). Additionally, pBOT3502 contains
five CDSs (CBOP15–CBOP19) that are dedicated to the
synthesis and secretion of the bacteriocin, boticin [14].
However apart from F9801A, no other strain gave a micro-
array signal for these probes, including C. botulinum strain
213B. This strain carries a plasmid bearing the genes for
boticin B [28], so might have been expected to give a pos-
itive signal. However, alignment of the 1 kb sequence
from strain 213B with that of pBOT3502 showed that
sequence identity over this region, spanning pBOT3502
CDSs CBOP16 and CBOP17, was only 52.1% which
would fail to give a positive microarray signal.
Isolation and mass spectrometry analysis of flagellin 
proteins
Flagellin proteins were isolated [29] and mass spectrome-
try studies of intact flagellin proteins were carried out as
described in earlier studies [30,31]. In some cases a large
precipitate was observed in dialysed flagellin prepara-
tions. Protein isolates were evaporated to dryness in a
Savant SpeedVac (Thermo Fisher Scientific UK) before
resuspending in 5–10 μl of formic acid. The sample was
agitated gently to dissolve protein and diluted 10-fold
with hexafluoroisopropanol. Samples were infused into a
hybrid quadrupole time-of-flight mass spectrometer
(Micromass Q-TOF2, Waters Corporation, MA, USA) at a
flow rate of 0.5–1.0 μl/min [30,31]. Top down mass spec-
trometry experiments were performed as described by
[30], using argon collision gas with collision energies
ranging from 20–30V.
Sequencing of sub-type A5 neurotoxin genes carried by 
wound botulism strains
To lower the risk of PCR-based errors, the A5 genes were
sequenced using non-cloned PCR products. Initial 3.8 kb
PCR products of the majority of the gene CDS were gener-
ated using a LongRange PCR kit (Qiagen, UK), with prim-
ers BONTAF1 (5'-GCAACCAGTAAAAGCTTTTAAAATTC-
3'), BONTAR1 (5'-CCATCCATCATCTACAGGAATAAA-3')
and 100 ng genomic DNA as template. PCR products were
purified using DyeEx 2.0 spin columns (Qiagen).
Sequencing was carried out using an AbiPrism 3730 cap-
illary sequencer. Sequence of the entire 3.8 kb PCR prod-
uct was achieved by designing primers using available
sequence data and by 'walking' forward on both strands.
Comparison of the 3.8 kb sequence with published exam-
ples of C. botulinum neurotoxin genes showed that the A5
neurotoxin sub-type was a close relative of the A1 sub-
type, which implied a similar neurotoxin locus structure.
Therefore to amplify DNA containing the 5' and 3' ends of
the A5 neurotoxin genes a series of PCR primers were
designed that would recognise the cntB gene (encodingBMC Genomics 2009, 10:115 http://www.biomedcentral.com/1471-2164/10/115
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NTNH) and the transposase that flank the A1 neurotoxin
gene of ATCC 3502 (CBO0805 and CBO0807 respec-
tively). PCR was performed using 'outward facing' primers
recognising the 3.8 kb sequence combined with these two
sets of primers. PCR products that were of the expected
size were sequenced. All sequencing fragments were
assembled using the ContigExpress programme of the
Vector NTI Advance 10 software package (Invitrogen).
Comparison of the completed A5 neurotoxin gene
sequence with that of published examples of other C. bot-
ulinum neurotoxin genes together with phylogenetic tree
construction was carried out using the AlignX programme
of this package. The A5 neurotoxin gene of four strains
associated with UK cases of wound botulism was
sequenced and found to be identical.
Accession Numbers
A representative of the sub-type A5 neurotoxin gene
sequence from wound botulism strain H0 4402 065 was
deposited in GenBank (accession number EU679004).
Microarray data have been deposited with Array Express
(accession number E-MEXP-1637).
Whole genome analysis of 61 strains of proteolytic C. botulinum and C. sporogenes Figure 1
Whole genome analysis of 61 strains of proteolytic C. botulinum and C. sporogenes. Each row of the heatmap repre-
sents a strain (indicated at right), and its branch on the dendrogram is coloured according to type of neurotoxin formed (indi-
cated at left of heatmap; spo refers to C. sporogenes). Although lost at this resolution, each microarray probe is represented by 
a vertical column within this row, from left to right first the 19 probes for each CDS of ATCC 3502 plasmid pBOT3502, fol-
lowed by probes for chromosomal CDSs, from CBO3648 to CBO001. The colour of each column in the heatmap is an indica-
tor of test signal over reference (ATCC 3502) signal channel ratio. Yellow columns represent probes which hybridised to both 
test and reference isolates equally, those in blue hybridised more strongly to the reference strain, and those in red hybridised 
more strongly to the test strain. Microarray features with fluorescent signals lower than 100 units (background noise), plus 
those CDSs not represented on the microarray are coloured grey. Distance measurements between 0 and 1.0 are indicated in 
the non-linear scale underneath the dendrogram. Clades 1 to 9 (brackets at right), are groups of strains which cluster at a dis-
tance measurement value of 0.3. The four main regions of variability (clusters of blue-coloured columns) are CDSs associated 
with pBOT3502, the Flagellar Glycosylation Island (FGI), and the two prophages, Φ-CB1 and Φ-CB2 (indicated above heat-
map).
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Results and discussion
Whole genome analysis
The 61 strains of proteolytic C. botulinum and C. sporogenes
tested in the present study were selected to represent
diverse origins. They had originally been isolated at differ-
ent times over a period of more than 80 years, from the
environment (17 strains (including unknowns)) or asso-
ciated with various forms of botulism (foodborne (20
strains), infant (17 strains), and wound (4 strains)). The
strains were of different toxin types; type A toxin gene (17
strains), type B toxin gene (16 strains), type F toxin gene
(3 strains), dual toxin genes (22 strains), and no toxin
gene (3 strains of C. sporogenes) (Table 1). The CDS con-
tent of the 61 test strains was indexed in relation to the
genome of proteolytic C. botulinum strain ATCC 3502
(Figure 1). The dendrogram and heatmap (Figure 1) were
derived from this whole genome analysis, and show that
all the strains of proteolytic C. botulinum and C. sporogenes
Heatmap comparison of CDSs in the Flagellar Glycosylation Island (FGI) Figure 2
Heatmap comparison of CDSs in the Flagellar Glycosylation Island (FGI). Top: See Figure 1 for explanation of heat-
map format. Strains are ordered by FGI CDS data; dendrogram and strain names at right are coloured (as for Figure 1) for type 
of neurotoxin formed. Filled triangles (bottom of heatmap): approximately 10 CDS intervals (data for some CDSs are absent). 
CDSs of FGI-I (CBO2666 – CBO2692) are highly conserved and those of FGI-II (CBO2696 – CBO2729) are less so. Hybridi-
sation profiles divided strains into 6 divisions, numbered at left. Mass of glycans detected by mass spectrometry analysis of FlaA 
proteins are symbolized in boxes at left. Strains examined by top down mass spectrometry are marked with a filled triangle. 
Top down profiles of flagellin from strains marked with a single asterisk and the complete structure of the posttranslational 
modification for strain FE9909ACS (hatch symbol) have been combined with previously published data [31]. Bottom: FGI 
sequence comparison of proteolytic C. botulinum strains ATCC 3502 (FGI division 2), top, and Langeland type F (FGI division 
3), below, confirms heatmap data. Synteny within FGI-I region (left) contrasts markedly with FGI-II; here ATCC 3502 contains 
approximately 20 CDSs not found in Langeland and displays less synteny and homology with the CDSs of the Langeland FGI-II. 
Heatmap data show that Langeland FGI contains many of the genes found in FGI-I of ATCC 3502 (yellow columns) while is still 
missing a large number of genes found in FGI-II of ATCC 3502 (blue columns).
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share a high degree of genetic relatedness (e.g. clustering
distance or branch-lengths in the dendrogram were short
with a high proportion of shared CDSs in the heatmap
(coloured yellow)). Most major branch points in the den-
drogram occurred at distance measurements of between
0.20 and 0.44. A distance measurement value of 0.30 sep-
arated the 61 strains of proteolytic C. botulinum and C. spo-
rogenes into nine clades (excluding ATCC 3502) (Figure
1). The strains did not group together according to the
location, environment, time of isolation, or the type of
botulism with which they were associated (Figure 1). This
lack of grouping probably reflects the wide range of
sources of the strains, and has been reported previously by
workers using other typing methods [8,32]. The predomi-
nance of yellow shading in the heatmap indicates that the
11 strains in clades 7 and 8 (Figure 1) were most closely
related to the reference strain (ATCC 3502). For example,
they shared the same FGI. While nine of fourteen type A1
neurotoxin strains (as ATCC 3502) were present in these
two clades, a type B and type F strain were also present.
Indeed, most clades contained strains of more than one
toxin type (or sub-type), and most toxin types (or sub-
types) were represented in more than one clade, suggest-
ing that the evolution of the neurotoxin genes has not par-
alleled that of the remainder of the genetic complement.
For example, clade 3 contains nine type B strains, one type
A1 strain, two type A2 strains, two type F and four type
A5(B) strains (the novel type A5(B) strains are described
below), and clade 9 contained two type B strains and three
C. sporogenes strains (Figure 1), confirming the close rela-
Plasmid pBOT3502 of strain ATCC 3502 shares CDSs with other strains of proteolytic C. botulinum Figure 3
Plasmid pBOT3502 of strain ATCC 3502 shares CDSs with other strains of proteolytic C. botulinum. Magnifica-
tion of the first 19 columns (probes for pBOT3502 CDSs) of the heatmap presented in Figure 1. Yellow/orange bars depict 
CDSs with significant homology to the probe; only strain F9801A possesses all 19 CDSs (CBOP1–CBOP19), suggesting it car-
ries a plasmid closely related to pBOT3502.
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tionship between proteolytic C. botulinum and C. sporo-
genes  (e.g. [2,8,14]). Two clades, however, contained
strains of just one toxin type. Clade 4 contained eight
closely-related North American-isolated type A1(B)
strains, and clade 7 comprised seven closely-related type
A1 strains (Figure 1). Clade 5 contained a single strain
(NCTC 2012, Loch Maree) that forms type A3 toxin. Inter-
estingly, other genomic indexing methods (MLST, AFLP,
VNTR) also found this strain to be unique and well sepa-
rated from other strains of proteolytic C. botulinum
[8,33,34]. In addition to the nine clades identified, further
sub-groupings were identified within each clade, often of
the same toxin type (or sub-type). Some strains appeared
highly similar to each other when compared to the
genome of ATCC 3502. These strains included the three
type Bf strains isolated from two patients and food follow-
ing a foodborne botulism outbreak in Quebec that
grouped closely together within clade 6, and the four
strains associated with wound botulism in the UK within
clade 3 (Figure 1). Most of the differences in microarray
data between the three type Bf strains were distributed
around the signal channel ratio cut-off point of 0.55, sug-
gesting that these apparent differences may reflect back-
ground noise associated with this type of analysis. Indeed,
it is likely that these three Bf strains are identical, as they
were isolated from a pâté and clinical samples from the
same outbreak. On the other hand, the wound botulism
strains showed some clear differences in their genetic con-
tent. Other genomic indexing methods (e.g. MLST, PFGE,
AFLP, VNTR) have given a broadly similar pattern to that
found in the present study, with groups of small numbers
of closely-related strains generally of the same toxin type
grouping together, with several distinct groups for each
toxin type [8,32-34]. There are, however, a number of
interesting anomalies that might be interpreted as evi-
dence for horizontally acquired genetic information, and
therefore worthy of further study, for example the type B
strain 2345 that groups most closely with the C. sporogenes
strains.
It is estimated that the core gene set for all 61 strains of
proteolytic C. botulinum and C. sporogenes tested was 2155
CDSs (Figure 5). This is approximately 63% of the CDSs
of ATCC 3502 represented by probes on the microarray,
and considerably higher than the value of 20% previously
reported for 75 strains of C. difficile [35]. This further con-
firms the close relationship of proteolytic C. botulinum
and C. sporogenes and indicates that exchange of genetic
information with other species has occurred less fre-
quently than in C. difficile. Apart from the neurotoxin
gene cluster itself, which although significant in terms of
biological impact, represents a very small part of the
genome, four main areas of divergence were identified;
the plasmid (pBOT3502), the flagellar glycosylation
island (FGI) and the two prophages (Figure 1). Together
these account for approximately 4.6% of the DNA (plas-
Restriction digests of plasmids carried by four strains of proteolytic C. botulinum Figure 4
Restriction digests of plasmids carried by four strains of proteolytic C. botulinum. Ethidium bromide-stained agarose 
gel photographed under UV light showing plasmid DNA extracted from four strains (indicated at bottom) following digestion 
with different restriction endonucleases (indicated at top). The plasmids carried by strains ATCC 3502 and by F9801A are 
clearly closely related or identical (see Figure 3). Lanes containing size markers (up to 10 kilobase pairs, kbp) are labelled M.
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mid plus chromosome) of ATCC 3502. It was previously
estimated that two type A1 strains shared 95–96% of their
CDSs with ATCC 3502 [14], but the two strains included
in this previous study are now revealed to be very close rel-
atives. Indeed, it was estimated that the core gene set for
the ten closely-related type A1 strains in clades 7 and 8
was 3055 CDSs, equating to 89% of the CDSs of ATCC
3502 (Figure 5).
Additionally, two strains of non-proteolytic C. botulinum
type E were tested, but too many CDSs were either absent
or highly diverged for meaningful data to be derived (data
not shown). It was previously reported that a strain of
non-proteolytic C. botulinum type B and a strain of C. dif-
ficile  were also too divergent to give a meaningful
response on this microarray [14]. The poor hybridisation
of DNA from the three strains of non-proteolytic C. botu-
linum to the microarray reflects the wide evolutionary and
phylogenetic distance between proteolytic C. botulinum
and non-proteolytic C. botulinum. This is a direct result of
the species "C. botulinum" being defined not on the basis
of a close evolutionary or phylogenetic relationship, but
on the basis of the disease caused [3].
Neurotoxin cluster arrangement – Single toxin gene strains
The type A1 neurotoxin gene is normally present in the ha
plus/orf-X minus type cluster, while the ha minus/orf-X
plus cluster is more commonly associated with type A2,
A3, A4 and F neurotoxin genes [9,36,37]. Twelve of the
fourteen type A1 neurotoxin strains tested contained the
ha plus/orf-X minus cluster, but in two strains (F9604A
and MUL0109ASA) the type A1 neurotoxin gene appears
to be in a ha minus/orf-X plus cluster (Figure 6). This
arrangement has also been recently reported for a small
number of other type A1 strains [18,38]. In the present
study, the genes (p47, orf-X1, orf-X2, orf-X3 and lycA) that
are only present in the ha minus/orf-X plus cluster were
always present together (26 strains), with no strain pos-
sessing only part of this cluster. The neurotoxin gene of
the two type A2 strains (NCTC 9837 and ZK3) and one
type A3 strain (NCTC 2012 – Loch Maree) was also
present in a ha minus/orf-X plus cluster (Figure 6), as
expected [9,13,18,37]. Although the two type A1 ha
minus/orf-X plus strains (F9604A and MUL0109ASA) had
the same neurotoxin cluster as the type A2 and A3 neuro-
toxin-forming strains (Figure 6), they were in different
clades well separated from each other and from the other
type A1 neurotoxin-forming strains (Figure 1). Instead
these two type A1 ha minus/orf-X plus strains grouped
with a type Ba strain (CDC 657) (Figure 1, clade 6). The
type A neurotoxin gene in strain CDC 657 (type A4) is
also in a ha minus/orf-X plus cluster [9]. Since previous
studies using AFLP, MLST and MVLA have shown two
other closely-related type A1 ha minus/orf-X plus strains
(CDC 297 and CDC 5328) also grouped with strain CDC
657 [8,33,34,38], it is likely that the four type A1 ha
minus/orf-X plus strains are closely related. Strain CDC
657 may have recently acquired a type B neurotoxin gene,
or the type A1 ha minus/orf-X plus strains may have lost a
type B neurotoxin gene. It is noted that the neurotoxin
genes in CDC 657 are present on a plasmid, while the type
A gene in at least one type A1 ha minus/orf-X plus strain
(CDC 5328) is located on the chromosome [39].
The 16 type B strains gave an almost identical hybridisa-
tion pattern, with all neurotoxin genes present in a ha
plus/orf-X minus cluster (Figure 6). This is consistent with
previous reports [9,12]. Strain MRB had a weak signal for
cntB (encoding NTNH), this may reflect the mosaic struc-
ture of cntB, and a previous genetic crossover event
between two types of neurotoxin gene cluster [2,9,40].
The three type F strains gave a ha minus/orf-X plus pattern
(Figure 6), an arrangement consistent with that reported
in the genome sequence for strain Langeland (CDSs
CLI_0845 to CLI_0850). However, while strains Lange-
land and Walls 8G grouped together in the whole genome
analysis (Figure 1, clade 3), strain H461297F grouped
with type A1 strains, providing further evidence that the
neurotoxin gene clusters are not evolutionarily tied to
their host organism [8,9,13].
The genes cntR/A1  and  cntR/F  (sometimes called p21)
encode closely related sigma 70 factors involved in regu-
Core set of CDSs of proteolytic C. botulinum/C. sporogenes Figure 5
Core set of CDSs of proteolytic C. botulinum/C. sporo-
genes. Microarray data were filtered to calculate numbers of 
CDSs which were shared by all strains at a given signal chan-
nel ratio. A cut-off value of 0.55 (arrows) was chosen as 
most appropriate to exclude CDSs that are absent or 
diverged from their ATCC 3502 counterparts. From the 
plots presented here this ratio value indicates a core set of 
2155 CDSs that are shared by all 61 strains tested (filled dia-
monds), and 3055 CDSs that are shared by all 10 C. botulinum 
ha plus/orf-X minus A1 strains in clades 7 and 8 (filled trian-
gles).
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Summary of microarray data for 16 neurotoxin gene cluster probes Figure 6
Summary of microarray data for 16 neurotoxin gene cluster probes. Names of proteolytic C. botulinum or C. sporo-
genes strains (left) are coloured according to type of neurotoxin(s) formed: red, A1; green, A2; ochre, A3; yellow, A1(B); pale 
yellow, A1b; orange, Ba4; pale blue, A5(B); blue, B; purple, Bf; lilac, F; magenta, C. sporogenes. Positive hybridisation results for 
microarray probes (above) are coloured green, borderline positives are pale green.
 
o
r
f
-
X
3
 
o
r
f
-
X
2
 
o
r
f
-
X
1
 
c
n
t
R
/
F
 
p
4
7
 
l
y
c
A
 
c
n
t
A
/
F
-
N
 
c
n
t
A
/
F
-
C
 
c
n
t
A
/
B
-
N
 
c
n
t
A
/
B
-
C
 
c
n
t
A
/
A
-
N
 
c
n
t
A
/
A
-
C
 
c
n
t
B
/
A
 
c
n
t
R
/
A
1
 
c
n
t
D
/
A
 
c
n
t
E
/
A
 
ATCC 3502
NCTC 3805
VL1 
16037
ATCC 25763
96A 
CDC 1690
NCTC 7272
17A 
F9801A
FE0101AJO
FE0205A1AK
F9604A
MUL0109ASA
NCTC 9837
ZK3 
NCTC 2012
NCTC 11199
CDC 5001
CDC 13280
MDa10
NCTC 2916
FE0207AMB
FE0303A1YO
FE9504ACG
FE9909ACS
PE0101AJO
FE0602ALS
CJ0611A
CDC 588
CDC 657
H0 4244 0055
H0 4402 065
H0 4464 107
H0 4068 0341
NCTC 7273
2345
NCTC 3815
BL81/25
213B
BL 143
BL 150
CDC 15044
NCIB 4301
CDC 7827
IB1-B
368B
920A276
FE0507BLP
13441-77
MRB
CDC 3281
FE9508BRB
FE9508BPD
PA9508B
Langeland
Walls 8G
H461297F
NCIMB 10696
NCDO 1792
NCDO 1710BMC Genomics 2009, 10:115 http://www.biomedcentral.com/1471-2164/10/115
Page 12 of 18
(page number not for citation purposes)
lation of the neurotoxin genes [9,13]. The probe designed
to be specific for cntR/A1 gave a positive result with all
strains that possessed a neurotoxin gene in a ha plus/orf-
X minus cluster (Figure 6). Similarly the probe designed to
be specific for cntR/F gave a positive result with all strains
that possessed a neurotoxin gene in a ha minus/orf-X plus
cluster (Figure 6). The type of neurotoxin regulatory gene
(cntR) present, therefore, is entirely in accordance with the
type of neurotoxin gene cluster, but not with the type of
neurotoxin gene.
Neurotoxin cluster arrangement – Dual toxin gene strains
Twenty-two strains tested in the present study possessed
two distinct neurotoxin genes. Fourteen of the dual gene
toxin strains possessed a type A1 and type B neurotoxin
gene. Two of these strains (CDC 657 and CDC 588) form
both neurotoxins, albeit in different proportions, while
the other 12 strains appear to form only type A neurotoxin
(Figure 6). All these 14 strains gave an identical response
in that they possessed complete ha plus/orf-X minus and
ha minus/orf-X plus clusters. The microarray data cannot
distinguish between dual toxin gene strains which carry a
type A1 toxin gene in a ha minus/orf-X plus cluster, and a
type B gene in a ha plus/orf-X minus cluster or vice-versa.
However, as all type B neurotoxin genes have been associ-
ated with a ha plus/orf-X minus cluster (Figure 6; [9,12]),
the simplest explanation is that the dual toxin gene strains
are in the former arrangement. This has been reported in
strains NCTC 2916 and CDC 657 [9,36,41] and from a
preliminary analysis of strains NCTC 11199, MDa10, 667
and CDC 588 [18,41]. The four strains that formed both
type B and type F toxin showed a similar hybridisation
profile to the A1(B) strains except that they possessed a
type F toxin gene rather than a type A toxin gene. Again
both the full ha plus/orf-X minus and ha minus/orf-X plus
clusters are present (Figure 6). It is likely that these strains
possess a type F gene in a ha minus/orf-X plus cluster, plus
a type B gene in a ha plus/orf-X minus cluster. This
hypothesis is supported by (i) this is the pattern found in
strains forming either type B or type F toxin, (ii) such an
arrangement was indicated by a preliminary analysis of
strain CDC 3281 [42], and (iii) was reported for a recently
sequenced unnamed Bf strain [GenBank:
NZ_ABDP00000000].
Identification of a new toxin sub-type
The present study included four strains of proteolytic C.
botulinum (H0 4244 0055, H0 4402 065, H04464 107, H0
4068 0341) that formed type A neurotoxin, and had been
isolated from patients presenting with wound botulism in
different regions of the UK in 2004. Whole genome anal-
ysis revealed that these strains formed a sub-group within
clade 3, distinct from other type A strains. Since the major-
ity of strains forming type A neurotoxin clustered together
within clades 4 or 7, this suggested the possibility that
they might represent an evolutionary distinct group which
could be sufficiently diverged to also produce a novel neu-
rotoxin sub-type (Figure 1). From the DNA sequence of
the entire cntA coding region, a translation product could
be predicted that comprised 1297 amino acid residues of
a type A neurotoxin gene. The cntA/A gene sequences from
all four strains were identical suggesting that these strains
may derive from a common source. Comparison with
published examples of neurotoxin A sub-types revealed
that the wound botulism-derived cntA/A genes were dis-
tinct from toxin sub-types A1 – A4 (Figures 7, 8 and 9;
Table 2). Subtypes of cntA are defined by a minimum of
2.6% difference between amino acid sequences [7,10].
The closest relative of the wound botulism-derived cntA/A
gene is the cntA/A1 gene (Table 2), and the new DNA
sequence predicts a 2.9% difference (37 amino acid resi-
dues) between the wound botulism-derived cntA/A genes
and the cntA/A1 genes, the latter tending to share approx-
imately 99.8% identity between themselves (see Figures 7
and 8 for an alignment of amino acid sequence of all five
sub-types). On this basis these wound botulism-derived
cntA/A genes define a new sub-type, and should be termed
cntA/A5. Furthermore, the four type A5(B) strains repre-
sented the only 'non-A1' neurotoxin-forming strains that
possessed a type A neurotoxin gene in a ha plus/orf-X
Table 2: Amino acid homology of neurotoxin A subtypes.
Strain ATCC 3502 Hall 183 CDC 297 Kyoto F NCTC 2012 CDC 657 H0 4402 065
ATCC 3502 100.0 (0)
Hall 183 99.8 (2) 100.0 (0)
CDC 297 99.6 (5) 99.6 (5) 100.0 (0)
Kyoto F 90.0 (130) 89.8 (132) 89.7 (134) 100.0 (0)
NCTC 2012 84.4 (202) 84.3 (204) 84.2 (205) 93.0 (91) 100.0 (0)
CDC 657 89.1 (141) 89.0 (143) 89.0 (142) 88.1 (154) 84.1 (206) 100.0 (0)
H0 4402 065 97.1 (37) 97.1 (38) 96.9 (40) 90.3 (125) 84.9 (196) 87.3 (165) 100.0 (0)
Pair-wise comparison of 1296 amino acid residue type A neurotoxins. ATCC 3502, Hall 183, CDC 297, type A1; Kyoto F, type A2; NCTC 2012, 
type A3; CDC 657, type A4; H0 4402 065, type A5. Bold figures: percent homology; figures in brackets: number of different residues. Only unique 
data are shown; A1 neurotoxins identical to that of strain ATCC 3502 include those of strains NCTC 3805 (62A), NCTC 7272 (ATCC 19397), and 
ATCC 25763. The A1 neurotoxin of Hall 183 is identical to that of the A1 (B) strain NCTC 2916. The Kyoto F A2 neurotoxin is identical to that of 
the FRI-Honey strain (all sequence data from GenBank). All type A5 neurotoxins described in this study are identical.BMC Genomics 2009, 10:115 http://www.biomedcentral.com/1471-2164/10/115
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Amino acid sequence alignment of proteolytic C. botulinum type A neurotoxin subtypes (part 1) Figure 7
Amino acid sequence alignment of proteolytic C. botulinum type A neurotoxin subtypes (part 1). Identical resi-
dues are in red; conservative differences are in white with blue background; blocks of similar residues are in black with green 
highlights; weakly similar residues are in green and non-similar residues are in black. Predicted amino acid sequences derive 
from published (GenBank) DNA sequence of: A1, ATCC 3502; A2, Kyoto F; A3, NCTC 2012; A4, CDC 657; A5, H0 4402 065 
(this work).
1                                                                                      100
A1 MPFVNKQFNY KDPVNGVDIA YIKIPNAGQM QPVKAFKIHN KIWVIPERDT FTNPEEGDLN PPPEAKQVPV SYYDSTYLST DNEKDNYLKG VTKLFERIYS
A2  MPFVNKQFNY KDPVNGVDIA YIKIPNAGQM QPVKAFKIHN KIWVIPERDT FTNPEEGDLN PPPEAKQVPV SYYDSTYLST DNEKDNYLKG VTKLFERIYS
A3  MPFVNKPFNY RDPGNGVDIA YIKIPNAGQM QPVKAFKIHE GVWVIPERDT FTNPEEGDLN PPPEAKQVPV SYYDSTYLST DNEKDNYLKG VIKLFDRIYS
A4  MPLVNQQIN YYDPVNGVDI AYIKIPNAGKM QPVKAFKIHN KVWVIPERDI FTNPEEVDLN PPPEAKQVPI SYYDSAYLST DNEKDNYLKG VIKLFERIYS
A5  MLFVNKQFNY KDPVNGVDIA YIKIPNAGQM QPVKAFKIHN KIWVIPERDT FTNPEEGDLN PPPEAKQVPV SYYDSTYLST DNEKDNYLKG VTKLFERIYS
101                                                                                    200
A1  TDLGRMLLTS IVRGIPFWGG STIDTELKVI DTNCINVIQP DGSYRSEELN LVIIGPSADI IQFECKSFGH EVLNLTRNGY GSTQYIRFSP DFTFGFEESL
A2  TDLGRMLLTS IVRGIPFWGG STIDTELKVI DTNCINVIQP DGSYRSEELN LVIIGPSADI IQFECKSFGH DVLNLTRNGY GSTQYIRFSP DFTFGFEESL
A3  TGLGRMLLSF IVKGIPFWGG STIDTELKVI DTNCINVIEP GGSYRSEELN LVITGPSADI IQFECKSFGH DVFNLTRNGY GSTQYIRFSP DFTFGFEESL
A4  TDLGRMLLIS IVRGIPFWGG GKIDTELKVI DTNCINIIQL DDSYRSEELN LAIIGPSANI IESQCSSFRD DVLNLTRNGY GSTQYIRFSP DFTVGFEESL
A5  TELGRMLLTS IVRGIPFWGG STIDTELKVI DTNCINVIQP DGSYRSEELN LVIIGPSADI IQFECKSFGH DVLNLTRNGY GSTQYIRFSP DFTFGFEESL
201                                                                                   300
A1  EVDTNPLLGA GKFATDPAVT LAHELIHAGH RLYGIAINPN RVFKVNTNAY YEMSGLEVSF EELRTFGGHD AKFIDSLQEN EFRLYYYNKF KDIASTLNKA
A2  EVDTNPLLGA GKFATDPAVT LAHELIHAEH RLYGIAINPN RVFKVNTNAY YEMSGLEVSF EELRTFGGHD AKFIDSLQEN EFRLYYYNKF KDVASTLNKA
A3  EVDTNPLLGA GTFATDPAVT LAHELIHAAH RLYGIAINPN RVLKVKTNAY YEMSGLEVSF EELRTFGGND TNFIDSLWQK KFSRDAYDNL QNIARILNEA
A4  EVDTNPLLGA GKFAQDPAVA LAHELIHAEH RLYGIAINTN RVFKVNTNAY YEMAGLEVSL EELITFGGND AKFIDSLQKK EFSLYYYNKF KDIASTLNKA
A5  EVDTNPLLGA GKFATDPAVT LAHELIHAGH RLYGIAINPN RVFKVNTNAY YEMSGLEVSF EELRTFGEHD AKFIDSLQEN EFRLYYYNKF KDIASTLNKA
301                                                                                   400
A1  KSIVGTTASL QYMKNVFKEK YLLSEDTSGK FSVDKLKFDK LYKMLTEIYT EDNFVKFFKV LNRKTYLNFD KAVFKINIVP KVNYTIYDGF NLRNTNLAAN
A2  KSIIGTTASL QYMKNVFKEK YLLSEDTSGK FSVDKLKFDK LYKMLTEIYT EDNFVNFFKV INRKTYLNFD KAVFRINIVP DENYTIKDGF NLKGANLSTN
A3  KTIVGTTTPL QYMKNIFIRK YFLSEDASGK ISVNKAAFKE FYRVLTRGFT ELEFVNPFKV INRKTYLNFD KAVFRINIVP DENYTINEGF NLEGAN-S--
A4  KSIVGTTASL QYMKNVFKEK YLLSEDATGK FLVDRLKFDE LYKLLTEIYT EDNFVKFFKV LNRKTYLNFD KAVFKINIVP DVNYTIHDGF NLRNTNLAAN
A5  KSIVGTTASL QYMKNVFKEK YLLSEDTSGK FSVDKLKFDK LYKMLTEIYT EDNFVKFFKV LNRKTYLNFD KAVFKINIVP EVNYTIYDGF NLRNTNLAAN
401                                                                                   500
A1 FNGQNTEINN MNFTKLKNFT GLFEFYKLLC VRGIITSKTK SLDKGYNKAL NDLCIKVNNW DLFFSPSEDN FTNDLNKGEE ITSDTNIEAA EENISLDLIQ
A2 FNGQNTEINS RNFTRLKNFT GLFEFYKLLC VRGIIPFKTK SLDEGYNKAL NDLCIKVNNW DLFFSPSEDN FTNDLDKVEE ITADTNIEAA EENISLDLIQ
A3  -NGQNTEINS RNFTRLKNFT GLFEFYKLLC VRGIIPFKTK SLDEGYNKAL NYLCIKVNNW DLFFSPSEDN FTNDLDKVEE ITADTNIEAA EENISSDLIQ
A4 FNGQNIEINN KNFDKLKNFT GLFEFYKLLC VRGIITSKTK SLDEGYNKAL NELCIKVNNW DLFFSPSEDN FTNDLDKVEE ITSDTNIEAA EENISLDLIQ
A5 FNGQNTEINN MNFTKLKNFT GLFEFYKLLC VRGIITSKTK SLDEGYNKAL NDLCIKVNNW DLFFSPSEDN FTNDLNKGEE ITSDTNIEAA EENISLDLIQ
501                                                                                   600
A1  QYYLTFNFDN EPENISIENL SSDIIGQLEL MPNIERFPNG KKYELDKYTM FHYLRAQEFE HGKSRIALTN SVNEALLNPS RVYTFFSSDY VKKVNKATEA
A2  QYYLTFDFDN EPENISIENL SSDIIGQLEP MPNIERFPNG KKYELDKYTM FHYLRAQEFE HGDSRIILTN SAEEALLKPN VAYTFFSSKY VKKINKAVEA
A3  QYYLTFDFDN EPENISIENL SSDIIGQLEP MPNIERFPNG KKYELDKYTM FHYLRAQEFE HGDSRIILTN SAEEALLKPN VAYTFFSSKY VKKINKAVEA
A4  QYYLNFNFDN EPENTSIENL SSDIIGQLEP MPNIERFPNG KKYELNKYTM FHYLRAQEFK HSNSRIILTN SAKEALLKPN IVYTFFSSKY IKAINKAVEA
A5  QYYLTFNFDN EPENISIENL SSDIIGQLEL MPNIERFPNG KKYELDKYTM FHYLRAQEFE HGKSRIVLTN SVNEALLNPS SVYTFFSSDY VRKVNKATEA
601                                                                                   700
A1 AMFLGWVEQL VYDFTDETSE VSTTDKIADI TIIIPYIGPA LNIGNMLYKD DFVGALIFSG AVILLEFIPE IAIPVLGTFA LVSYIANKVL TVQTIDNALS
A2 FMFLNWAEEL VYDFTDETNE VTTMDKIADI TIIVPYIGPA LNIGNMLSKGE FVEAIIFTG VVAMLEFIPE YALPVFGTFA IVSYIANKVL TVQTINNALS
A3 VIFLSWAEEL VYDFTDETNE VTTMDKIADI TIIVPYIGPA LNIGNMVSKGE FVEAILFTG VVALLEFIPE YSLPVFGTFA IVSYIANKVL TVQTINNALS
A4 VTFVNWIENL VYDFTDETNE VSTMDKIADI TIVIPYIGPA LNIGNMIYKGE FVEAIIFSG AVILLEIVPE IALPVLGTFA LVSYVSNKVL TVQTIDNALS
A5 AMFLGWVEQL VYDFTDETSE VSTTDKIADI TIIIPYIGPA LNIGNMLYKD DFVGALIFSG AVILLEFIPE IAIPVLGTFA LVSYIANKVL TVQTIDNALS
701                                                                                   800
A1  KRNEKWDEVY KYIVTNWLAK VNTQIDLIRK KMKEALENQA EATKAIINYQ YNQYTEEEKN NINFNIDDLS SKLNESINKA MININKFLNQ CSVSYLMNSM 
A2  KRNEKWDEVY KYTVTNWLAK VNTQIDLIRE KMKKALENQA EATKAIINYQ YNQYTEEEKN NINFNIDDLS SKLNESINSA MININKFLDQ CSVSYLMNSM 
A3  KRNEKWDEVY KYTVTNWLAK VNTQIDLIRE KMKKALENQA EATRAIINYQ YNQYTEEEKN NINFNIDDLS SKLNRSINRA MININKFLDQ CSVSYLMNSM 
A4  KRNEKWDEVY KYIVTNWLAI VNTQINLIRE KMKKALENQA EATKAIINYQ YNQYTEEEKN NINFNIDDLS SKLNESINSA MININKFLDQ CSVSYLMNSM 
A5  KRNEKWGEVY KYIVTNWLAK VNTQIDLIRK KMKEALENQA EATKAIINYQ YNQYTEEEKN NINFNIGDLS SKLNDSINKA MININKFLNQ CSVSYLMNSM 
801                                                                                   900
A1  IPYGVKRLED FDASLKDALL KYIYDNRGTL IGQVDRLKDK VNNTLSTDIP FQLSKYVDNQ RLLSTFTEYI KNIINTSILN LRYESNHLID LSRYASKINI
A2  IPYAVKRLKD FDASVRDVLL KYIYDNRGTL VLQVDRLKDE VNNTLSADIP FQLSKYVDNK KLLSTFTEYI KNIVNTSILSI V YKKDDLID LSRYGAKINI
A3  IPYAVKRLKD FDASVRDVLL KYIYDNRGTL ILQVDRLKDE VNNTLSADIP FQLSKYVNDKK LLSTFTEYI KNIVNTSILSI V YKKDDLID LSRYGAKINI
A4  IPYAVKRLKD FDASVRDVLL KYIYDNRGTL IGQVNRLKDK VNNTLSADIP FQLSKYVDNK KLLSTFTEYI KNITNASILSI V YKDDDLID LSRYGAEIYN
A5  IPYGVKRLED FDASLKDALL KYIYDNRGTL IGQVDRLKDK VNNTLSTDIP FQLSKYVDNQ RLLSTFTEYI KNIINTSILN LRYESNHLID LSRYASEINI
901                                                                                  1000
A1  GSKVNFDPID KNQIQLFNLE SSKIEVILKN AIVYNSMYEN FSTSFWIRIP KYFNSISLNN EYTIINCMEN NSGWKVSLNY GEIIWTLQDT QEIKQRVVFK
A2  GDRVYYDSID KNQIKLINLE SSTIEVILKN AIVYNSMYEN FSTSFWIKIP KYFSKINLNN EYTIINCIEN NSGWKVSLNY GEIIWTLQDN KQNIQRVVFK
A3  GDRVYYDSID KNQIKLINLE SSTIEVILKN AIVYNSMYEN FSTSFWIKIP KYFSKINLNN EYTIINCIEN NSGWKVSLNY GEIIWTLQDN KQNIQRVVFK
A4  GDKVYYNSID KNQIRLINLE SSTIEVILKK AIVYNSMYEN FSTSFWIRIP KYFNSISLNN EYTIINCMEN NSGWKVSLNY GEIIWTFQDT QEIKQRVVFK
A5  GSKVNFDPID KNQIQLFNLE SSKIEIILKN AIVYNSMYEN FSTSFWIKIP KYFSKINLNN EYTIINCIEN NSGWKVSLNY GEIIWTLQDN KQNIQRVVFK
1001                                                                                    1100
A1  YSQMINISDY INRWIFVTIT NNRLNNSKIY INGRLIDQKP ISNLGNIHAS NNIMFKLDGC RDTHRYIWIK YFNLFDKELN EKEIKDLYDN QSNSGILKDF
A2  YSQMVNISDY INRWIFVTIT NNRLTKSKIY INGRLIDQKP ISNLGNIHAS NKIMFKLDGC RDPRRYIMIK YFNLFDKELN EKEIKDLYDS QSNSGILKDF
A3  YSQMVNISDY INRWMFVTIT NNRLTKSKIY INGRLIDQKP ISNLGNIHAS NKIMFKLDGC RDPRRYIMIK YFNLFDKELN EKEIKDLYDS QSNPGILKDF
A4  YSQMINISDY INRWIFVTIT NNRITKSKIY INGRLIDQKP ISNLGNIHAS NKIMFKLDGC RDPHRYIVIK YFNLFDKELS EKEIKDLYDN QSNSGILKDF
A5  YSQMVAISDY INRWIFITIT NNRLNNSKIY INGRLIDQKP ISNLGNIHAS NNIMFKLDGC RDPHRYIWIK YFNLFDKELN EKEIKDLYDN QSNSGILKDFBMC Genomics 2009, 10:115 http://www.biomedcentral.com/1471-2164/10/115
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minus cluster (Figure 6). Interestingly all four type A5
strains gave a positive signal with the C-terminal type B
probe. Following a combination of DNA sequencing and
PCR analysis, the presence of a near complete type B neu-
rotoxin gene with the 5' end (i.e. N-terminus of protein)
either absent or diverged from previously published
examples was detected (data not shown). As such, these
strains also represent the first published examples of type
A(B) strains that lack the ha minus/orf-X plus cluster for
neurotoxin genes. Since active type B toxin was not
detected in the mouse test, they are designated as type
A5(B). Wound botulism cases in the UK are associated
with heroin abuse [43], and it is likely that the source of
these strains of proteolytic C. botulinum is the same as the
heroin, which comes from Afghanistan [44]. This may
indicate that previously unknown botulinum neurotoxin
types are present in this part of Asia; the majority of pub-
lished botulinum neurotoxin gene sequences are from
strains originating in Europe or North America.
The amino acid residue differences that distinguish the A5
sub-type from the four other type A sub-types are scattered
throughout its length (Figures 7 and 8; [7-9]). The N-ter-
minal eight amino acid residues are involved in binding
to the neuronal cell plasma membrane [45]. Significantly
the A5 neurotoxin has a leucine at position 2, in contrast
to the usual proline, an amino acid known to cause
marked conformational changes in peptide secondary
structure. The C terminus of the light chain, especially res-
idues 398–448 is important for solubility, stability and
catalysis [46], but only one residue (E444) close to the
protease nicking site differs in this region. Similarly, of the
heavy chain residues that are proposed to build the lactose
and sialyllactose-binding pockets needed for ganglioside
binding [47], only L1278 has been changed (to an F). It is
tempting to predict from this in silico study that the gene
product of cntA/A5 will share a similar toxicity to that of
cntA/A1, although the fact that at least three residues
known to be functionally important are different may
have important implications.
Relationship to C. sporogenes
The type B toxin producing strain 2345 had a weak signal
for all four neurotoxin-associated probes (Figure 6), and
Amino acid sequence alignment of proteolytic C. botulinum type A neurotoxin subtypes (part 2) Figure 8
Amino acid sequence alignment of proteolytic C. botulinum type A neurotoxin subtypes (part 2). Identical resi-
dues are in red; conservative differences are in white with blue background; blocks of similar residues are in black with green 
highlights; weakly similar residues are in green and non-similar residues are in black. Predicted amino acid sequences derive 
from published (GenBank) DNA sequence of: A1, ATCC 3502; A2, Kyoto F; A3, NCTC 2012; A4, CDC 657; A5, H0 4402 065 
(this work).
1101                                                                                  1200
A1  WGDYLQYDKP YYMLNLYDPN KYVDVNNVGI RGYMYLKGPR GSVMTTNIYL NSSLYRGTKF IIKKYASGNK DNIVRNNDRV YINVVVKNKE YRLATNASQA 
A2  WGNYLQYDKP YYMLNLFDPN KYVDVNNIGI RGYMYLKGPR GSVVTTNIYL NSTLYEGTKF IIKKYASGNE DNIVRNNDRV YINVVVKNKE YRLATNASQA 
A3  WGNYLQYDKP YYMLNLFDPN KYVDVNNIGI RGYMYLKGPR GSVMTTNIYL NSTLYMGTKF IIKKYASGNE DNIVRNNDRV YINVVVKNKE YRLATNASQA 
A4  WGDYLQYDKS YYMLNLYDPN KYVDVNNVGI RGYMYLKGPR DNVMTTNIYL NSSLYMGTKF IIKKYASGNK DNIVRNNDRV YINVVVKNKE YRLATNASQA 
A5  WGNYLQYDKP YYMLNLYDPN KYVDVNNVGI RGYMYLKGPR GSIVTTNIYL NSSLYMGTKF IIKKYASGNK DNIVRNNDRV YINVVVKNKE YRLATNASQA 
1201                                                                              1296
A1  GVEKILSALE IPDVGNLSQV VVMKSKNDQG ITNKCKMNLQ DNNGNDIGFI GFHQFNNIAK LVASNWYNRQ IERSSRTLGC SWEFIPVDDG WGERPL
A2  GVEKILSALE IPDVGNLSQV VVMKSKDDQG IRNKCKMNLQ DNNGNDIGFI GFHLYDNIAK LVASNWYNRQ VGKASRTFGC SWEFIPVDDG WGESSL
A3  GVEKILSALE IPDVGNLSQV VVMKSKDDQG IRNKCKMNLQ DNNGNDIGFV GFHLYDNIAK LVASNWYNRQ VGKASRTFGC SWEFIPVDDG WGESSL
A4  GVEKILSALE IPDVGNLSQV VVMKSKNDQG ITNKCKMNLQ DNNGNDIGFI GFHQFNNIAK LVASNWYNRQ IERSSRTLGC SWEFIPVDDG WRERPL
A5  GVEKILSVLE IPDVGNLSQV VVMKSKNDQG IRNKCKMNLQ DNNGNDIGFI GFHQFNNIDK LVASNWYNRQ IERSSRTFGC SWEFIPVDDG WGESPL
Relatedness of C. botulinum type A neurotoxins Figure 9
Relatedness of C. botulinum type A neurotoxins. The dendrogram was generated with the AlignX (ClustalW) pro-
gramme of the Vector NTI Advance 10 (Invitrogen) software package, using data presented in Table 2 and Figures 7 and 8. Fig-
ures in brackets refer to the number of amino acid residues different to those of the A1 neurotoxin of ATCC 3502.
A1 ATCC 3502
A1 Hall 183 (2)
A1 CDC 297 (5)
A2 Kyoto F (130)
A3 Loch Maree (202)
A4 CDC 657 (141)
A5 H0 4402 065 (37)BMC Genomics 2009, 10:115 http://www.biomedcentral.com/1471-2164/10/115
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also groups together with the three C. sporogenes strains in
the whole genome analysis (Figure 1). These observations
support a hypothesis that strain 2345 may represent a
strain of C. sporogenes which has recently acquired part of
the (or a diverged but intact) neurotoxin gene cluster in
the recent evolutionary past. Interestingly, two of the three
C. sporogenes strains, which were expected to be com-
pletely negative for all neurotoxin-associated probes, gave
a weak signal to the cntR/A1 probe (Figure 6). This could
be due to the presence of a distantly related or partial cntR
gene, implying that these C. sporogenes strains may either
represent a descendent of C. botulinum that have lost most
of their ha plus/orf-X minus neurotoxin gene cluster, or
may have acquired a neurotoxin gene cluster by horizon-
tal gene transfer (as postulated for strain 2345), but then
subsequently lost most of it. Although not the same strain
as the three used in this work, BLAST searches of the pre-
dicted peptides of the (unfinished) C. sporogenes strain
ATCC 15579 genome sequence showed that of several
proteolytic C. botulinum examples of this gene (and one
non-proteolytic  C. botulinum example, that of strain
Eklund 17B), CntR of ATCC 3502 gave the highest per-
centage identity (48%) over the longest unbroken stretch
of peptide sequence. Whereas this tends to support the
microarray data, the stretch of sequence was only 27
amino acid residues in length, so genome sequence anal-
ysis of more C. sporogenes strains would be needed to fur-
ther investigate this interesting observation.
Evolution of neurotoxin genes in relationship to the 
genome
It is evident that in strains of proteolytic C. botulinum, the
distribution of neurotoxin genes and neurotoxin cluster
type are not consistent with the whole genome analysis
(Figure 6, Figure 1). This is consistent with previous
reports by other genomic indexing methods (e.g. 16S rrn,
PFGE, AFLP, MLST [2,8,32,33]). The evolutionary pat-
terns of neurotoxin and associated genes within the neu-
rotoxin cluster are also incompatible, and are likely to
have arisen from several distinct recombination events.
For example, the present study has confirmed earlier
reports [18,38] that in type A1 strains, the neurotoxin
genes may be located in a ha plus/orf-X minus cluster or
in a ha minus/orf-X plus cluster. It was also found that the
cntR gene correlated with neurotoxin cluster type, rather
than neurotoxin gene. Previous reports have identified
that NTNH-encoding genes also correlated with neuro-
toxin cluster type rather than neurotoxin gene, and that
the middle of the NTNH gene may be a hot-spot for
recombination events within the neurotoxin cluster
[2,9,13]. Putative insertion sequence (IS) elements
located close to the neurotoxin cluster and the localisation
of neurotoxin genes on large plasmids may also have
played a role in mobilisation and gene transfer of neuro-
toxin and associated genes [9,39].
Flagellar glycosylation island (FGI)
Microarray analysis of the CDSs within the FGI separated
strains into six divisions. Divisions 1 and 2 had similar
profiles, with division 1 missing some CDSs contained
within FGI-II. Divisions 3–6 were all missing large sec-
tions of FGI-II, with division 5 also missing CDSs within
FGI-I (Figure 2). The structure of these divisions indicates
that, as seen for the neurotoxin cluster genes, the evolu-
tion of the FGI may have occurred independently of the
remainder of the genetic complement, with most divi-
sions containing strains of more than one toxin type and
from more than one clade. Divisions 1–3 each contained
strains of at least four toxin types (or sub-types) that
belonged to three or more clades, while division 4 con-
tained only type B strains from clade 3, and division 5
comprised only the strains in clade 9 (type B and C. sporo-
genes strains). Division 6 contained just one strain, 17A.
The genetic variation highlighted by these divisions (Fig-
ure 2) forms the basis for a typing method for proteolytic
C. botulinum [29].
The genetic repertoire of the FGI indicated by the microar-
ray analysis suggested that the glycan biosynthetic capac-
ity of these C. botulinum strains may vary (Figure 2).
Indeed, it has been shown that strains differ in their FlaA
glycan structure, and it is proposed that FGI-II is involved
in this process [29,31]. Flagellin proteins were isolated
from representative strains in each division to determine
the nature of the glycan produced and its correlation with
FGI microarray profiles. Top down MS analysis of intact
flagellin protein revealed diversity in glycan composition
amongst isolates [30,31]; the masses of which are shown
in Figure 2. Flagellin from the majority of strains in divi-
sion 1 harboured a glycan oxonium ion at m/z 259. Fur-
ther characterisation of this glycan by MS/MS showed
fragmentation ions at m/z 200.1, 182.1, 158.1, 154.1,
126.1 and 112.1, characteristic of a di-N-acetylhexuronic
acid, previously identified as part of a trisaccharide modi-
fication on Methanococcus voltae flagellin [48]. Many of the
flagellins of division 2 strains carried a glycan oxonium
ion at m/z 301. The MS/MS spectrum of this ion also
shared fragmentation ions with a di-N-acetylhexuronic
acid, but with the increased mass likely to correspond to
the addition of a third acetyl group (data not shown). A
glycan oxonium ion at m/z 418 was detected as the FlaA
modification on all division 3 strains examined. This FlaA
glycan has been fully characterized in strain FE9909ACS
as a novel legionaminic acid derivative, Leg5Ac7NMeGlu
[31]. Strains 920A276 and CDC 15044 from division 4
possessed flagellins with glycan oxonium ions at m/z 417
and 431, which shared glycan oxonium ion fragmenta-
tion patterns typical of nonulosonic acid sugars (data not
shown). The flagellin of the division 5 strain FE0507BLP
had a glycan oxonium ion at m/z 317, which had the char-
acteristic MS/MS fragmentation pattern of the nonu-BMC Genomics 2009, 10:115 http://www.biomedcentral.com/1471-2164/10/115
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losonic acid sugars pseudaminic and legionaminic acid
(data not shown). These sugars have been structurally
characterised from the flagellins of Campylobacter jejuni
[49], Campylobacter coli [50] and Helicobacter pylori [51].
Taken together, these observations show that differences
in the FGI microarray profiles may be reflected in the mass
of glycan oxonium ions that modify the flagellin. Interest-
ingly, top down mass spectrometry analysis of FlaA from
strain 17A did not produce any marker ions characteristic
of glycan, although the mass of the protein is greater than
could be predicted from its DNA sequence. This indicates
that it too is probably post-translationally modified [29].
In this case a 'bottom up' mass spectrometry analysis of
flagellar tryptic peptides may be required to identify the
glycan moiety.
A representative of division 3, which appears to produce
the novel legionaminic acid derivative, Leg5Ac7NMeGlu,
is the type F strain Langeland, the genome of which has
been recently sequenced. Comparison of FGI sequences of
both Langeland and ATCC 3502 showed that CDSs of
FGI-I shared at least 80% identity, while FGI-II was highly
divergent and was 30 kb smaller in strain Langeland (Fig-
ure 2). Homologues to the biosynthetic genes for legion-
aminic acid synthesis in Campylobacter coli have been
identified in the FGI-II region of the Langeland genome
[31]. The definitive confirmation that CDSs in FGI-II are
responsible for biosynthesis of the glycan found on C. bot-
ulinum  strain Langeland FlaA, however, awaits further
genetic analysis.
Previously, nonulosonic acid sugars such as legionaminic
acid and pseudaminic acid have been identified as the
post-translational modification of flagellins in the Gram-
negative gastrointestinal pathogens, Campylobacter  and
Helicobacter [52]. In these bacteria, the glycosylation of the
flagellin is essential for filament assembly and glycan
modifications have been shown to play a role in patho-
genesis [53,54]. The presence of nonulosonic acid sugars
in numerous strains of C. botulinum may have an impor-
tant bearing on its ability to establish a gut infection and
thereby cause infant or adult intestinal botulism.
Although the present study has not correlated the distri-
bution of specific flagellin glycan modifications with the
type of botulism caused, this property may enable a strain
to bring about infant/adult intestinal botulism at a lower
infectious dose than that of strains lacking these flagellin
modifications. A comparative genomic analysis of Campy-
lobacter jejuni identified distinct distributions of flagellar
glycosylation genes (cj1321–cj1326) that were present
only in strains associated with colonisation of livestock
[53]. The hypothesis was developed that the type of flag-
ellar glycosylation genes in Campylobacter jejuni strains
conferred a survival advantage to these strains within live-
stock, offering a possible explanation for the host specifi-
city of some Campylobacter jejuni strains. It remains to be
established whether diversity in flagellar glycan biosyn-
thetic capacity in C. botulinum is similarly related to host
specificity and the colonization ability of isolates.
Conclusion
The most important aspects of the biology and evolution
of proteolytic C. botulinum have been highlighted by this
study, particularly in relation to the neurotoxin and its
associated cluster and the FGI. The close relationship with
C. sporogenes, and very distant relationship with non-pro-
teolytic C. botulinum have been confirmed. Proteolytic C.
botulinum and non-proteolytic C. botulinum are phyloge-
netically distinct organisms that coincidentally share type
B and type F neurotoxin genes. These genes are of such
sequence similarity as to obviously share a recent com-
mon ancestor, and appear therefore to have crossed the
species barrier. Intriguingly, type A and type E neurotoxin
genes seem to be mutually exclusive and are each
restricted to just one of these species. The genome of pro-
teolytic C. botulinum appears to be relatively stable, and
strains sequenced to date display a high degree of synteny
(data not shown). There are, however, variable regions,
and we have presented evidence for the independent hor-
izontal transfer of genes encoding the neurotoxin cluster
and FGI, compared to the remainder of the genetic com-
plement. Transfer of neurotoxin and associated genes may
be associated with a hot-spot for recombination within
the NTNH, closely associated IS elements, and plasmids.
Further investigations of unexpected toxin or FGI types
within clades may be particularly interesting, and reveal
more about the acquisition or loss of genetic material. For
example, while most type A1 strains grouped together
according to whole genome and FGI analysis, four
appeared to be distinct. Two of these type A1 strains,
FE9604A and MUL0109ASA were closely related to each
other, with the toxin gene in a ha minus/orf-X plus cluster.
Strains 17A and 96A were both ha plus/orf-X minus
strains, but appear to be different to each other and all the
other type A1 strains by whole genome and FGI analysis.
Interestingly, strain 96A was also well separated from
other type A1 strains by PFGE [32]. The sequencing of fur-
ther strains (which is rapidly becoming affordable for
most laboratories) is a particularly attractive way forward,
as unlike microarray analysis, which can only highlight
CDSs that are present or absent in a test strain, it will pro-
vide information not only on what has been inserted or
lost, but where on the genome this has taken place.
Indeed the genomes of several of the strains used in this
study have recently been sequenced, and those with
slightly larger genomes typically also carry approximately
300–600 novel genes with respect to the ATCC 3502
strain used as a reference in this work (data not shown).
A number of typing tools have been used for the molecu-
lar characterisation of proteolytic C. botulinum. Some (e.g.
ribotyping, 16S rrn sequencing) can be used to identifyBMC Genomics 2009, 10:115 http://www.biomedcentral.com/1471-2164/10/115
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the organism, but are not particularly effective at discrim-
inating between strains [8,55]. Others (e.g. PFGE, MLST,
AFLP, VNTR, fla sequencing, DNA microarrays) are able to
discriminate between strains [8,14,29,32-34]. The present
study and previous work [14] have demonstrated that
comparative genomic indexing using a DNA microarray
based on the genome sequence of ATCC 3502 is an effec-
tive tool to discriminate strains of proteolytic C. botuli-
num. Advantages of microarrays are that they can infer
evolutionary relationships better than single/multi-locus
methods and additionally provide valuable information
on the genome content of tested strains, thereby provid-
ing an insight into the biology and evolution of the organ-
ism. The present microarray is suitable for the forensic
analysis of strains of proteolytic C. botulinum, including
investigations of bioterrorism associated events. A second
generation DNA microarray could be developed for this
purpose based on the variable regions identified between
a number of sequenced strains, and utilise printed rather
than spotted microarrays.
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